Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2191 to 2205 of 8220 results

  1. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development Reference number: GID-NG10404 Expected publication date: TBC

    NICE guideline
    In development

  2. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease [TSID11791]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years [TSID10350]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 [TSID11807]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation